Back

Mdivi-1 reduces blood pressure in gastric cancer-bearing nude mice by ameliorating apatinib-induced Drp1-mediated excessive mitochondrial fission

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardioprotection and cardiovascular safety in contemporary cancer therapies Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Jing Yu

Lanzhou University Second Hospital, Lanzhou (China)

4 More presentations in this session

Presentation thumbnail
Distinct blood pressure variability phenotype in VEGF–TKI–induced hypertension: a comparative study across cardio-oncology populations
Doctor H. Yu (Lanzhou, CN)
Abstract Slides Video
Presentation thumbnail
Systematic review and network meta-analysis of cardio-protective therapies in cancer patients
Doctor V. Maharajan (London, GB)
Abstract Slides Video
Presentation thumbnail
Cardiovascular safety of next-generation BTK inhibitors versus ibrutinib in CLL/SLL: a systematic review and meta-analysis of randomised controlled trials
Mr B. Temer Teixeira Goldwasser (BR)
Abstract Slides Video
Presentation thumbnail
Validation of a deep learning–based workflow for echocardiographic interpretation in a cardio-oncology population
Doctor M. Andres (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Cardioprotection and cardiovascular safety in contemporary cancer therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
The new mechanism of apatinib in treating gastric cancer-related hypertension: dynamin-related protein 1-mediated pathological mitochondrial fission in endothelial cells
1 September 2025
thumbnail
Congress Presentation
Cancer treatment-induced arterial hypertension
21 June 2025
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019
thumbnail
Congress Presentation
Myeloperoxidase inhibitor AZD4831 target engagement and safety in a phase 2a study in patients with heart failure with preserved ejection fraction (SATELLITE)
1 July 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources